A Single-arm, Multi-center, Open-label Phase II Study to Determine the Safety and Efficacy of MB-CART2019.1 in Pediatric Subjects With Relapsed/Refractory (r/r) Mature B-cell Neoplasms Who Have Relapsed After One or More Prior Therapies, Including Subjects With Primary Refractory Disease

This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and <18 years, ≥6 kg body weight [BW]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.

开始日期2025-04-01

申办/合作机构

Miltenyi Biomedicine GmbH初创企业

NCT06708845

/ Not yet recruiting临床1期

A Phase I Multicohort Trial of Zamtocabtagene Autoleucel (Zamto-Cel) in Subjects with Severe Refractory Autoimmune Diseases

AID is a phase I multi-cohort study to assess the safety and tolerability of zamtocabtagene autoleucel (zamto-cel) in patients with refractory autoimmune diseases (SLE-Non renal, SLE-LN, SSc/dcSSc) after receiving standard therapy.

开始日期2025-01-01

申办/合作机构

Miltenyi Biomedicine GmbH初创企业

100 项与 Zamtocabtagene autoleucel 相关的临床结果

登录后查看更多信息

100 项与 Zamtocabtagene autoleucel 相关的转化医学

登录后查看更多信息

100 项与 Zamtocabtagene autoleucel 相关的专利（医药）

登录后查看更多信息

项与 Zamtocabtagene autoleucel 相关的文献（医药）

2024-10-01·RMD Open

Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel

Article

作者: Heteren, Pearl van ; Holtkamp, Silke ; Remenyi, Peter ; Overstijns, Toon ; Balogh, Alexandra ; Paksi, Melinda ; Gopcsa, Laszlo ; Szabo, David ; Reti, Marienn ; Nagy, György ; Giba-Kiss, Laura ; Zadoyan, Gregor ; Lakatos, Gergely ; Miltenyi, Stefan ; Takacs, Peter

We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.

100 项与 Zamtocabtagene autoleucel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
难治性成熟B细胞非霍奇金淋巴瘤	临床2期	-	Miltenyi Biomedicine GmbH初创企业	2025-04-01
狼疮性肾炎	临床1期	-	Miltenyi Biomedicine GmbH初创企业	2025-01-01
弥漫性硬皮病	临床1期	-	Miltenyi Biomedicine GmbH初创企业	2025-01-01